Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 28:18:17562864251356062.
doi: 10.1177/17562864251356062. eCollection 2025.

Neuropsychiatric disorders in Parkinson's disease

Beatrice Heim  1 , Atbin Djamshidian  2
Affiliations
Review

Neuropsychiatric disorders in Parkinson's disease

Beatrice Heim et al. Ther Adv Neurol Disord. .

Abstract

Neuropsychiatric symptoms, such as depression, anxiety, cognitive changes, apathy or hallucinations are common in patients with Parkinson's disease (PD). They can appear at any stage of the disease and some symptoms may even be a harbinger of PD. These neuropsychiatric complications often become more pronounced as PD progresses and may worsen particularly during 'off-periods'. Moreover, neuropsychiatric symptoms are also frequently seen in patients with addictive behaviours, collectively called impulse control disorders, where insight is particularly low. In this narrative review, non-pharmacological as well as experimental and pragmatic pharmacological approaches are outlined to provide a deeper understanding of the best treatment strategy for these patients. Early detection as well as a tailored multidisciplinary approach is necessary to improve symptoms and ultimately the quality of life for patients and their family members.

Keywords: Parkinson’s disease; impulse control disorder; neuropsychiatric symptoms.

PubMed Disclaimer

References

    1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021; 397(10291): 2284–2303. - PubMed
    1. Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of Parkinson’s disease: advances and challenges. Lancet Neurol 2022; 21(1): 89–102. - PMC - PubMed
    1. Rukavina K, Batzu L, Boogers A, et al. Non-motor complications in late stage Parkinson’s disease: recognition, management and unmet needs. Expert Rev Neurother 2021; 21(3): 335–352. - PubMed
    1. Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes – key to understanding heterogeneity. Nat Rev Neurol 2021; 17(6): 349–361. - PubMed
    1. Mueller C, Rajkumar AP, Wan YM, et al. Assessment and management of neuropsychiatric symptoms in Parkinson’s disease. CNS Drugs 2018; 32(7): 621–635. - PubMed

LinkOut - more resources